Matthew Squires

3.1k total citations
71 papers, 1.9k citations indexed

About

Matthew Squires is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Matthew Squires has authored 71 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Molecular Biology, 30 papers in Oncology and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Matthew Squires's work include Melanoma and MAPK Pathways (12 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers) and Cancer-related Molecular Pathways (11 papers). Matthew Squires is often cited by papers focused on Melanoma and MAPK Pathways (12 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers) and Cancer-related Molecular Pathways (11 papers). Matthew Squires collaborates with scholars based in United States, Switzerland and United Kingdom. Matthew Squires's co-authors include Simon J. Cook, John F. Lyons, Margaret M. Manson, E A Hudson, Neil T. Thompson, Sally A. Prigent, Donna-Michelle Smith, Edward J. Lewis, Lynne Howells and Nicola G. Wallis and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Matthew Squires

70 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew Squires United States	25	1.1k	825	414	262	253	71	1.9k
Ramasamy Jagadeeswaran United States	22	1.1k 1.0×	601 0.7×	732 1.8×	125 0.5×	202 0.8×	47	2.3k
Christine Fritsch Switzerland	21	1.8k 1.6×	610 0.7×	401 1.0×	134 0.5×	387 1.5×	39	2.6k
Haluk Yuzugullu France	10	1.4k 1.2×	541 0.7×	307 0.7×	116 0.4×	226 0.9×	12	1.8k
Donna Headlee United States	24	1.5k 1.3×	1.1k 1.3×	559 1.4×	259 1.0×	236 0.9×	34	2.7k
Anne T. Truesdale United States	13	1.1k 0.9×	972 1.2×	505 1.2×	145 0.6×	142 0.6×	16	2.3k
Maria Luisa Veronese United States	18	969 0.9×	678 0.8×	340 0.8×	115 0.4×	136 0.5×	35	1.8k
Sohye Kang United States	16	1.9k 1.7×	695 0.8×	379 0.9×	145 0.6×	450 1.8×	18	2.4k
Erzsébet Rásó Hungary	29	1.1k 1.0×	840 1.0×	409 1.0×	200 0.8×	65 0.3×	90	2.2k
Ramzi M. Mohammad United States	28	1.1k 1.0×	788 1.0×	175 0.4×	134 0.5×	194 0.8×	74	1.9k
Lorelei J. Hanson United States	15	1.1k 1.0×	971 1.2×	411 1.0×	85 0.3×	86 0.3×	20	1.8k

Countries citing papers authored by Matthew Squires

Since Specialization

Citations

This map shows the geographic impact of Matthew Squires's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Squires with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Squires more than expected).

Fields of papers citing papers by Matthew Squires

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Squires. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Squires. The network helps show where Matthew Squires may publish in the future.

Co-authorship network of co-authors of Matthew Squires

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Squires. A scholar is included among the top collaborators of Matthew Squires based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Squires. Matthew Squires is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schöffski, Patrick, Yemarshet K. Gebreyohannes, Thomas Van Looy, et al.. (2022). In Vivo Evaluation of Fibroblast Growth Factor Receptor Inhibition in Mouse Xenograft Models of Gastrointestinal Stromal Tumor. Biomedicines. 10(5). 1135–1135. 5 indexed citations

Wiggins, Jennifer, Georgina V. Long, Keith T. Flaherty, et al.. (2021). Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. The Lancet Oncology. 22(3). 370–380. 70 indexed citations

Dummer, Reinhard, Jan C. Brase, James E. Garrett, et al.. (2020). Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. The Lancet Oncology. 21(3). 358–372. 85 indexed citations

Musolino, Antonino, Mario Campone, Patrick Neven, et al.. (2017). Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Research. 19(1). 18–18. 87 indexed citations

Corcoran, Ryan B., Thierry André, Takayuki Yoshino, et al.. (2016). Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC). Annals of Oncology. 27. vi150–vi150. 36 indexed citations

Rybkin, Igor I., Egbert F. Smit, Hans‐Georg Kopp, et al.. (2016). PS01.60: Ph Ib/II, Trial of INC280 ± Erlotinib vs Platinum + Pemetrexed in Adult pts with EGFR-Mutated, cMET amplified, EGFR TKI Resistant, Advanced NSCLC. Journal of Thoracic Oncology. 11(11). S307–S308. 1 indexed citations

Bauer, Todd M., Martin Schüler, Rossana Berardi, et al.. (2016). MINI01.03: Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC. Journal of Thoracic Oncology. 11(11). S257–S258. 11 indexed citations

Wolf, Jennifer Moriatis, Maximilian J. Hochmair, Joseph Kattan, et al.. (2015). 478TiP A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease. Annals of Oncology. 26. ix125–ix125. 2 indexed citations

Sonkin, Dmitriy, Michael R. Palmer, Catherine H. Régnier, et al.. (2015). The identification and characterization of a STAT5 gene signature in hematologic malignancies. Cancer Biomarkers. 15(1). 79–87. 7 indexed citations

10.

Escudier, Bernard, Viktor Grünwald, Alain Ravaud, et al.. (2014). Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer. Clinical Cancer Research. 20(11). 3012–3022. 49 indexed citations

11.

Milowsky, Matthew I., Christian Dittrich, Ignacio Durán, et al.. (2014). Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. European Journal of Cancer. 50(18). 3145–3152. 82 indexed citations

12.

Arkenau, Hendrik‐Tobias, Ruth Plummer, L. Rhoda Molife, et al.. (2011). A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Annals of Oncology. 23(5). 1307–1313. 52 indexed citations

13.

Qi, Wenqing, Xiaobing Liu, Laurence Cooke, et al.. (2011). AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B‐cell lymphomas. International Journal of Cancer. 130(12). 2997–3005. 45 indexed citations

14.

Dawson, Mark A., Jayne Curry, Philip Beer, et al.. (2010). AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. British Journal of Haematology. 150(1). 46–57. 41 indexed citations

15.

Santo, Loredana, Sonia Vallet, Teru Hideshima, et al.. (2010). AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition. Oncogene. 29(16). 2325–2336. 114 indexed citations

16.

Squires, Matthew, Ruth E. Feltell, Nicola G. Wallis, et al.. (2009). Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Molecular Cancer Therapeutics. 8(2). 324–332. 134 indexed citations

17.

Tanaka, Ruriko, Matthew Squires, Shinya Kimura, et al.. (2008). Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models.. Blood. 112(11). 1104–1104. 6 indexed citations

18.

Dickinson, Robin J., et al.. (2007). DUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK5. Cellular Signalling. 20(5). 836–843. 72 indexed citations

19.

Squires, Matthew, E A Hudson, Lynne Howells, et al.. (2003). Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells. Biochemical Pharmacology. 65(3). 361–376. 166 indexed citations

20.

Manson, Margaret M., Andreas J. Gescher, E A Hudson, et al.. (2000). Blocking and suppressing mechanisms of chemoprevention by dietary constituents. Toxicology Letters. 112-113. 499–505. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact